IGC Pharma
27 hedge funds and large institutions have $1.01M invested in IGC Pharma in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 0 closing their positions.
336% more call options, than puts
Call options by funds: $48K | Put options by funds: $11K
22% more capital invested
Capital invested by funds: $827K → $1.01M (+$186K)
17% more funds holding
Funds holding: 23 → 27 (+4)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0.24% more ownership
Funds ownership: 5% → 5.24% (+0.24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$40.2K |
| 2 |
VF
Virtu Financial
New York
|
+$25K |
| 3 |
Jane Street
New York
|
+$16.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$11.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$27.1K |
| 2 |
BlackRock
New York
|
-$13.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.37K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$492 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DFA
26
DHJJ Financial Advisors
Naperville,
Illinois
| $29 | +$29 | +80 | New |
|
27
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $2 | – | – | – |
|
IGC Hedge Fund Activity: Q3 2023 in Review
27 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2023, worth a combined $1.01M — up 22% from $827K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IGC positions and 0 closed out — a net gain of 4 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Commonwealth Equity Services, adding an estimated $40.2K. The largest seller was Renaissance Technologies, cutting an estimated $27.1K.
- 27 institutional investors held IGC Pharma (IGC) as of Q3 2023, up from 23 in Q2 2023.
- Funds reported $1.01M of IGC Pharma stock for Q3 2023, up 22% quarter-over-quarter.
- 4 funds opened new IGC Pharma positions in Q3 2023 and 0 closed out, a net change of +4 holders.
- The largest IGC Pharma buyer in Q3 2023 was Commonwealth Equity Services, an estimated $40.2K added.
- The largest IGC Pharma seller in Q3 2023 was Renaissance Technologies, an estimated $27.1K sold.
Based on aggregated 13F filings for Q3 2023.